Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of avelumab-treated participants from multiple parent studies
jRCT2080224625Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of avelumab in cancer, sponsored by Merck KGaA. Started Apr 2019; status: completed.
02
Drugs
avelumab
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080224625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224625.